Optimer Pharmaceuticals (OPTR) Misses Q2 EPS by 6c

Article Stock Quotes (1) Comments (0)

Optimer Pharmaceuticals (NASDAQ: OPTR) reported Q2 EPS of ($0.01), $0.06 worse than the analyst estimate of $0.05. Revenue for the quarter came in at $49.8 million versus the consensus estimate of $49.47 million.

As of June 30, 2012, we held cash, cash equivalents and short-term investments of $130.6 million. This amount includes the $53.6 million milestone payment from Astellas Pharmaceuticals Europe recognized in the fourth quarter of 2011. We had 47,531,412 shares outstanding on June 30, 2012.

For earnings history and earnings-related data on Optimer Pharmaceuticals (OPTR) click here.

---

Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW

---

*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here

---

---

You May Also Be Interested In

• Abercrombie & Fitch Co. (ANF) Misses Q1 EPS by 4c; Guides FY Below Views
• Pandora Media (P) Reports In-Line Q1 EPS, Revenue & Guidance Beat
• Marvell Technology Group (MRVL) Tops Q1 EPS by 5c; Issues Solid Outlook

Create E-mail Alert Related Categories

Earnings

Related Entities

Earnings

Add Your Comment

Name

Subject

Body

Share on Facebook

Verification
can't see the text?
click here to refresh the image.
what's this?